Heat Biologics (HTBX) Trading Down 30.7%

Heat Biologics Inc (NASDAQ:HTBX) traded down 30.7% during trading on Wednesday . The stock traded as low as $1.37 and last traded at $1.42. 5,485,197 shares were traded during trading, an increase of 561% from the average session volume of 829,592 shares. The stock had previously closed at $2.05.

Several equities research analysts recently commented on the company. Brookline Cap M reaffirmed a “buy” rating on shares of Heat Biologics in a research report on Wednesday, August 1st. HC Wainwright set a $6.00 price objective on Heat Biologics and gave the company a “buy” rating in a research report on Friday, November 16th. Finally, ValuEngine raised Heat Biologics from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st.

Heat Biologics (NASDAQ:HTBX) last released its quarterly earnings data on Thursday, November 15th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.05. Heat Biologics had a negative return on equity of 94.53% and a negative net margin of 331.02%. The company had revenue of $1.84 million for the quarter, compared to analysts’ expectations of $1.50 million. As a group, analysts forecast that Heat Biologics Inc will post -1.03 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in Heat Biologics stock. Northern Trust Corp bought a new position in Heat Biologics Inc (NASDAQ:HTBX) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 51,512 shares of the biopharmaceutical company’s stock, valued at approximately $111,000. Northern Trust Corp owned about 0.22% of Heat Biologics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 3.96% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Heat Biologics (HTBX) Trading Down 30.7%” was posted by WKRB News and is owned by of WKRB News. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.wkrb13.com/2018/11/23/heat-biologics-htbx-trading-down-30-7.html.

Heat Biologics Company Profile (NASDAQ:HTBX)

Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.

Read More: How to Invest in Marijuana Stocks

Receive News & Ratings for Heat Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply